PET/MR doesn’t appear to provide any additional insight beyond PET/CT for thoracic staging of non-small cell lung cancer, according to a study published Feb. 6 in the Journal of Nuclear Medicine.

Three major patient advocacy associations, the Alzheimer’s Association, the Michael J. Fox Foundation and the W. Garfield Weston Foundation, have joined forces to encourage researchers to explore the biological bridges between Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

The global market for medical reagents, including those used for molecular imaging purposes, is expected to grow substantially through 2016, according to a market report announced Feb. 5 from research firm TechNavio.

FluoroPharma Medical, based in Montclair, N.J., announced yesterday that new results from an ongoing phase II clinical trial for F-18 FCPHA cardiac PET for the diagnosis of acute coronary artery disease (CAD) were positive and providing validation for further research.

A partnership between MPI Research, 3D Imaging and inviCRO has led to a new translational imaging center complete with on-site cyclotron that recently broke ground in Mattawan, Mich. The institution is scheduled to open this spring, according to the Feb. 5 announcement from MPI.

Angiography cannot differentiate between vulnerable and stable plaques, which inform clinicians about a patient’s risk of rupture. Immuno-imaging with SPECT/CT could be a route for marking increased immune response at the site of high-risk vulnerable plaques, but there remain some complications, according to a study published Jan. 21 in Molecular Imaging.

Navidea Biopharmaceuticals, producers of the amyloid PET agent NAV4694, announced Feb. 2 that CEO Mark Pikett, PhD, would hold a presentation at the 16th annual BIO CEO and Investor Conference taking place at the Waldorf Astoria in New York City, Feb. 10-11.

A comparison of PET/MR and PET/CT using a trimodality system showed that PET/MR is a worthy alternative, if not superior, to PET/CT when imaging for head and neck tumors, according to a study published Feb. 3 in in the Journal of Nuclear Medicine.